Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS
· Delayed Price · Currency is USD
14.80
0.00 (0.00%)
At close: Mar 7, 2025
Teva Pharmaceutical Industries Employees
As of December 31, 2024, Teva Pharmaceutical Industries had 35,686 total employees, including 33,892 full-time and 1,794 part-time employees. The number of employees decreased by 786 or -2.16% compared to the previous year.
Employees
35,686
Change (1Y)
-786
Growth (1Y)
-2.16%
Revenue / Employee
$475,553
Profits / Employee
-$47,113
Market Cap
18.45B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 35,686 | -786 | -2.16% |
Dec 31, 2023 | 36,472 | 1,347 | 3.83% |
Dec 31, 2022 | 35,125 | -854 | -2.37% |
Dec 31, 2021 | 35,979 | -2,393 | -6.24% |
Dec 31, 2020 | 38,372 | -1,667 | -4.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 2,931 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 413 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
Silence Therapeutics | 109 |
Longduoduo Company | 49 |
Teva Pharmaceutical Industries News
- 6 days ago - Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds - Seeking Alpha
- 8 days ago - Deckers Outdoor Corp (DECK) Unveils Teva's Spring-Summer 2025 Collection - GuruFocus
- 9 days ago - Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March - GlobeNewsWire
- 12 days ago - Teva Pharmaceutical: A Risky Bet With Potential Upside - Seeking Alpha
- 13 days ago - 2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals - GlobeNewsWire
- 15 days ago - FDA accepts Teva's application for Uzedy for bipolar I disorder - Seeking Alpha
- 15 days ago - Teva Pharmaceutical's UZEDY sNDA Accepted by FDA for Bipolar I Disorder Treatment - GuruFocus
- 15 days ago - Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder - GlobeNewsWire